glp 1 drugs and inflammation The anti-inflammatory feature of glucagon-like peptide-1 its based diabetes drugs—Therapeutic potential exploration in lung injury Glucagon-like peptide-1: a multi-faceted anti-inflammatory

New data is illuminating the full profile of GLP-1 side effects

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

GLP-1 weight loss treatments can come with side effects

The trial was conducted in parallel in Japan, France, England, Mexico, Denmark, the USA and Germany as part of an international, randomized, double-blind study

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they